TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02670616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 560 mg by mouth daily on day 1-21 per each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV, day 1
Study: NCT00726219

Intervention type: OTHER
Group type: OTHER
Intervention: Femoral perineural catheter
Description: Comparison of 2 insertion distances (3 vs 7 cm) for a femoral perineural catheter in the context of major knee surgery.

Intervention type: OTHER
Group type: OTHER
Intervention: Femoral perineural catheter
Description: Comparison of 2 insertion distances (3 vs 7 cm) for a femoral perineural catheter in the context of major knee surgery.
Study: NCT05023590

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ablation of left atrium during mitral valve open chest intervention
Description: open chest mitral valve surgery (reconstruction or replacement) with additional ablation of left atrium by cryo or radio frequency method

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ablation of left atrium during mitral valve open chest intervention
Description: open chest mitral valve surgery (reconstruction or replacement) with additional ablation of left atrium by cryo or radio frequency method
Study: NCT03854916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caminemos Juntas App
Description: A tailored mobile app that encourages Latinas and Hispanic women to walk together using location-based services.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: World Walking App
Description: A mobile app that encourages users to walk.
Study: NCT00140075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin with Cyclophosphamide, followed by a Taxane
Description: Epirubicin = 90 mg/m2 Cyclophosphamide = 600 mg/m2~Followed by a taxane; paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin with a Taxane
Description: Epirubicin = 75 mg/m2 per cycle~Taxane = paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2
Study: NCT02863978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal signal acquisitions
Description: Cardiac and respiratory signals are collected from the clinical monitoring routinely gathered in hospital neonatal units.~Movement quantification and baby's sounds are extracted thanks to a dedicated system which will collect images and sound with microphones and cameras.
Study: NCT03643003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Music therapy consists of live singing of participant-preferred music, with guitar accompaniment, by a board-certified music therapist (i.e., MT-BC), following a protocol regarding how to manipulate the music in real time per participant responses. Dosage: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon.
Study: NCT02670616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 IV day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 IV day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: 1.4 mg/m2 IV on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 100mg per day on day 1-5
Study: NCT03665740

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Resveratrol
Description: resveratrol is an OTC supplement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: resveratrol is an OTC supplement
Study: NCT02687451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymorphone HCl
Description: Oral liquid and injection; dose to be determined by Independent Data Monitoring Committee (IDMC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymorphone HCl
Description: Oral liquid and injection; dose to be determined by Independent Data Monitoring Committee (IDMC).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator for the double-blinded, placebo-controlled multiple-dose phase.
Study: NCT01236469

Intervention type: PROCEDURE
Intervention: Echocardiogram
Description: A prospective follow-up Study Echocardiogram will be performed, as applicable, for those subjects who do not have echo data as of January 1, 2009.
Study: NCT02813915

Intervention type: DEVICE
Intervention: NICOM
Description: Use of NICOM and PLR to obtain patient fluid status
Study: NCT04369391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP363856 150 mg
Description: SEP363856 tablet 150 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin 400 mg
Description: moxifloxacin tablet 400 mg
Study: NCT01780701

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Spectroscopy Imaging with rectal probe

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Spectroscopy Imaging with rectal probe
Study: NCT00613769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trimethoprim-sulfamethoxazole + metronidazole
Description: trimethoprim-sulfamethoxazole (160mg/800mg)p.o.+ metronidazole (1200mg)p.o.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefuroxime and metronidazole
Description: cefuromime 1500mg i.v. + metronidazole 1500mg i.v.
Study: NCT04088812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo meat derivative + Placebo satiating compound
Description: Subjects will consume 60 g of meat derivative placebo in a brunch type meal with 25 g of the satiating compound placebo diluted in water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo meat derivative + Placebo satiating compound
Description: Subjects will consume 60 g of meat derivative placebo in a brunch type meal with 25 g of the satiating compound placebo diluted in water
Study: NCT03643003

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Music therapy
Description: Music therapy consists of live singing of participant-preferred music, with guitar accompaniment, by a board-certified music therapist (i.e., MT-BC), following a protocol regarding how to manipulate the music in real time per participant responses. Dosage: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Music Verbal Interaction (Placebo)
Description: Non-music verbal interaction consists of conversation of participants' interests, without music, by a board-certified music therapist, following a protocol regarding how to respond verbally in real time per participant responses. Dosage is the same as for music therapy: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-Music Verbal Interaction (Placebo)
Description: Non-music verbal interaction consists of conversation of participants' interests, without music, by a board-certified music therapist, following a protocol regarding how to respond verbally in real time per participant responses. Dosage is the same as for music therapy: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon.
Study: NCT00937638

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BOLD Diet
Description: Low-fat, high fruit and vegetable diet that includes lean beef (5oz/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BOLD-X Diet
Description: Low-fat, moderate-high protein diet (BOLD+) that is higher in total protein (from mixed sources including lean beef, 7oz/day) than the BOLD diet. Also high in fruits and vegetables

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified DASH Diet
Description: Low-fat, high fruit and vegetable diet which has become the Gold Standard for the management of cardiovascular disease (CVD) risk factors and metabolic syndrome
Study: NCT00129233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: valsartan 80 to 160 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 5 to 10 mg daily.
Study: NCT03212703

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Skills Training (MBST)
Description: 8-week mindfulness skills training sessions based on Mindfulness-Based Cognitive Therapy (MBCT) program by Zindel Segal, Mark Williams and John Teasdale

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist control (WLC)
Description: Observation surveys at baseline, mid-point and end-point of an 8-week period
Study: NCT03794843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimodipine Injection
Description: Nimodipine injection (trade name: Nimotop) manufactured by Bayer Pharma AG was used as the reference preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimodipine Injection (II)
Description: Nimodipine Injection (II) was supplied by Shenyang Dongxing Pharmaceutical Technology Co., Ltd
Study: NCT02634138

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revitive IX
Description: A foot plate Neuromuscular Electrical Stimulation Device
Study: NCT01570023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Isometric Progressive Resistance Oropharyngeal Therapy
Description: Tongue press exercises consist of pressing the tongue against the sensors. Isometric exercises will focus on the anterior and posterior sensor. Subjects will be given a target pressure value for both the anterior and posterior sensor locations for which to aim when doing the exercises. Visual feedback on the display will signal the subject that they have attained their target pressure goal.
Study: NCT03734848

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Ultrasound Guided Pectoralis Nerve Block.
Description: Using a 20-gauge 5 cm needle. Injection bupivacaine 0.25% used as a local anesthetic. The block was performed in a supine position with the arm slightly abducted. The ultrasound probe was placed at the midclavicular level infero-laterally to locate the axillary artery and vein and then moved laterally toward the axilla until pectoralis major, pectoralis minor, and serratus anterior muscles were identified at the level of the fourth rib. The needle was inserted in-plane with respect to the ultrasound probe. A volume of 20 ml of local anesthetic solution was deposited in the fascial plane between pectoralis minor and serratus anterior muscle, followed by withdrawal of the needle to the fascial plane between the pectoralis major and pectoralis minor muscle, where a volume of 10 ml was deposited. The block was performed similarly on the opposite side. Care was taken not to cross the toxic dose of bupivacaine (3 mg/kg).
Study: NCT01690039

Intervention type: DRUG
Intervention: Furosemide-Fludrocortisone-Test (test for urinary acidification)
Description: The presence of a lack of urinary acidification will be assessed by an appropriate test in all patients.
Study: NCT02310191

Intervention type: PROCEDURE
Intervention: Carotid stenting
Description: Procedures will be carried out via the femoral approach following a Seldinger technique. All patients will be on long-term aspirin (100 mg/day) and a 525-mg loading dose of clopidogrel. A dose of 10 000 units unfractionated heparin will be administered at the beginning of the intervention. A cerebral protection device (FilterWire EZ™; Boston Scientific, Natick, Massachusetts, USA) will be use in all patients if possible. The type of covered stent and other specific intervention strategies will be left to the discretion of the interventional radiologists. After predilatation of the stenosis (if needed), an appropriate stent for each stenosis will be implanted and then dilated using a balloon catheter.
Study: NCT02720926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda,
Description: Capecitabine (xeloda): 2000mg/m2, twice a day on Day 1-14;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 130mg/m2 day 1 every 21days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Description: 4 dose levels of TKI258: 200mg, 300mg, 400mg, 500mg once daily, 5days on and 2 days off;
Study: NCT01298024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Neuromuscular Exercise
Description: 30 patients are randomized to early neuromuscular exercise (n=15) or treatment as usual, i.e., late exercise (n=15). Both groups are given an orthosis and are instructed to wear this for eight weeks. The experimental group starts with a structured exercise program one week after the diagnosis. The patients attend one training session/week during eight weeks, guided by a physical therapist. The level of training is progressed during this time. The patients in the control group (treatment as usual) are given exercise instructions and information at one occasion; 2 weeks after diagnosis. Both groups are followed up, by a blinded assessor, with valid and reliable self-reported and physical function outcomes at 1, 4, 8 and 16 weeks after injury.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early Neuromuscular Exercise
Description: 30 patients are randomized to early neuromuscular exercise (n=15) or treatment as usual, i.e., late exercise (n=15). Both groups are given an orthosis and are instructed to wear this for eight weeks. The experimental group starts with a structured exercise program one week after the diagnosis. The patients attend one training session/week during eight weeks, guided by a physical therapist. The level of training is progressed during this time. The patients in the control group (treatment as usual) are given exercise instructions and information at one occasion; 2 weeks after diagnosis. Both groups are followed up, by a blinded assessor, with valid and reliable self-reported and physical function outcomes at 1, 4, 8 and 16 weeks after injury.
Study: NCT00481728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine
Description: Single dose per patient as determined by protocol.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Filling cystometry
Description: This is a procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravesical neurostimulation
Description: This is a procedure.
Study: NCT02821884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combination of tDCS and NMES
Description: Both tDCS and NMES conduct simultaneously for 30 minutes. The anodal electrode of tDCS is placed on the scalp site corresponding to primary motor cortex (M1) of the hemisphere affected by stroke. The cathodal electrode of tDCS is placed on the scalp site corresponding to unaffected primary motor cortex. The current is initially increased in a ramp-like fashion over 30 seconds until reaching 2 mA and is decreased ramp-like fashion over 30 seconds until reaching 0 mA. The NMES electrodes are placed over the following muscle: extensor digitorum communis, extensor carpi radialis to produce wrist and hand extension. The settings for the NMES is frequency at 50 Hz, pulse width of 200μs,duty cycle of 10 seconds on and 10 seconds off,current amplitude is adjusted to patients comfort (10-20mA).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Combination of tDCS and sham NMES
Description: Both tDCS and sham NMES conduct simultaneously for 30 minutes. The anodal electrode of tDCS is placed on the scalp site corresponding to primary motor cortex (M1) of the hemisphere affected by stroke. The cathodal electrode of tDCS is placed on the scalp site corresponding to unaffected primary motor cortex. The current is initially increased in a ramp-like fashion over 30 seconds until reaching 2 mA and is decreased ramp-like fashion over 30 seconds until reaching 0 mA. Sham NMES electrodes are placed away from all extensor digitorum communis, extensor carpi radialis motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation(wrist extension).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Combination of sham tDCS and sham NMES
Description: Both sham tDCS and sham NMES conduct simultaneously for 30 minutes. Sham tDCS electrodes are placed in the same position on patients receiving the sham stimulation. Just like during real tDCS, stimulation is started in a ramp-like fashion but fade out slowly after 30 seconds. Sham NMES electrodes are placed away from all extensor digitorum communis, extensor carpi radialis motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation(wrist extension).
Study: NCT02919670

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enterade

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Supportive Care

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Supportive Care
Study: NCT00993096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
Study: NCT01332734

Intervention type: DRUG
Intervention: Magnesium Sulfate
Description: 2 gram in 1 hour
Study: NCT03949075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: Participants will be assigned to daily administration of ACE inhibitors (Initially 5 mg Corodil® 'Enalapril' daily followed by up to 20 mg daily dependent on the blood pressure response) combined with an 8-week training period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be assigned to daily administration of placebo (5-20 mg CaCO3) combined with an 8-week training period.
Study: NCT01332617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.
Description: 1. Simvastatin 80 mg PO daily starting day -2 through day 10.~2. Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly~3. Bortezomib 1.3 mg/m2/day IV bolus on days 3,6 and 10.~4. Bendamustine 100 mg/m2/day IV over 30 minute infusion on days 3 and 10.~5. Methylprednisolone 1g/m2 IV over 30 minutes on days 1 and 8.
Study: NCT04569045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HA+Lidocaine
Description: 20 mg

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HA
Description: 20 mg
Study: NCT01829932

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Factor Altered Diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Factor Altered Diet
Study: NCT01506531

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: silo for gastroschisis
Description: silo placed around abdominal contents in gastroschisis patients
Study: NCT03840278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bihormonal iLet Bionic Pancreas
Description: Bihormonal iLet Bionic Pancreas using insulin and dasiglucagon

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin-only Bionic Pancreas
Description: Insulin-only iLet Bionic Pancreas using just insulin
Study: NCT01506531

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary closure of gastroschisis
Description: Primary closure of gastroschisis, if possible
Study: NCT04024475

Intervention type: OTHER
Intervention: Observation

Intervention type: OTHER
Intervention: Observation

Intervention type: OTHER
Intervention: Observation

Intervention type: OTHER
Intervention: Observation

Intervention type: OTHER
Intervention: Observation
Study: NCT04301167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: befriending
Description: Participants are new users of the ALONE befriending intervention, which matches participants to volunteer befrienders who visit once weekly for a minimum of 12 months. It is a criterion of study involvement that participants commit to completing at least two data collection timepoints before being matched to a befriender.
Study: NCT04127760

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Radiotherapy would start within 2 months after the operation, and 5 days of radiotherapy is performed every week. The dose of each radiotherapy is 1.8 Gy for 6 weeks, and the total dose is 54 Gy.
Study: NCT00996762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: 1250 mg or 1500 mg lapatinib commercial tablet
Study: NCT02281721

Intervention type: DEVICE
Intervention: Surpass Flow Diverter(s)
Description: Endovascular placement of a Surpass Flow Diverter(s) for the treatment of an intracranial aneurysm(s)
Study: NCT02821585

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional Counseling
Description: Carbohydrate counting will be reviewed, as well as hypoglycemia management. The 9 following visits will focus on different aspects of each diets: types of fats, meat and alternatives, grain products, milk and alternatives, fruits and vegetables, salt intake, energy density and restaurants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Counseling
Description: Carbohydrate counting will be reviewed, as well as hypoglycemia management. The 9 following visits will focus on different aspects of each diets: types of fats, meat and alternatives, grain products, milk and alternatives, fruits and vegetables, salt intake, energy density and restaurants.